newsfilter
← Latest News
PR Newswire·

Mallinckrodt Announces Enrollment of First Patient in Phase 1/2a StrataSOMA Clinical Trial of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for Investigating the Treatment of Full-Thickness Burns

DUBLIN, Dec. 16, 2021 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ), a global biopharmaceutical company, today announced enrollment of the first patient in StrataSOMA, a Phase 1/2a clinical trial that is assessing StrataGraft® (allogeneic cultured kera